Holen Sie sich die Stockscreener-App
1.79
7.01%
-0.135
Schlusskurs vom Vortag:
$1.925
Offen:
$1.94
24-Stunden-Volumen:
1.38M
Relative Volume:
1.03
Marktkapitalisierung:
$214.48M
Einnahmen:
$6.65M
Nettoeinkommen (Verlust:
$-136.32M
KGV:
-1.5596
EPS:
-1.1477
Netto-Cashflow:
$-112.04M
1W Leistung:
-17.89%
1M Leistung:
-26.64%
6M Leistung:
+30.66%
1J Leistung:
+16.23%
1-Tages-Spanne:
$1.78
$1.975
1-Wochen-Bereich:
$1.78
$2.18
52-Wochen-Spanne:
$0.95
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.79 | 214.48M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-19 | Fortgesetzt | Jefferies | Buy |
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView
Fate Therapeutics stock stands 97.96 percent higher year to date - ad-hoc-news.de
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Singapore
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance UK
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy By Investing.com - Investing.com Nigeria
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy - Investing.com
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com South Africa
Fate Therapeutics appoints Jamie Harrell to lead commercialization - Investing.com
Fate Therapeutics appoints Jamie Harrell to lea... - Pluang
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com Canada
Fate Therapeutics names Jamie Harrell SVP of commercial operations - StreetInsider
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies - GlobeNewswire Inc.
Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan
Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Consensus Target Price of $5.90 - MarketBeat
Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock - AD HOC NEWS
Fate Therapeutics stock adds two Q4 conference dates - AD HOC NEWS
Fate Therapeutics stock gained 4.74 percent on October 5 - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving AverageTime to Sell? - marketbeat.com
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Australia
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay - stocktitan.net
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics, Inc. (F6T.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire Inc.
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire
FRAUD AND MANIPULATION—S.D. Cal.: Pharma company ducks securities fraud claim for lack of loss causation - VitalLaw.com
Gross profit of Fate Therapeutics, Inc. – HAN:F6T - TradingView
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial - Yahoo Finance
Fate Therapeutics receives $15m CIRM grant for lupus trial - Investing.com
Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Announces Receipt of California Institute - GlobeNewswire
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN - Yahoo Finance
Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK
Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - Yahoo Finance
A study explores cell therapy without preparatory chemotherapy. Fate will present four at ACR. - stocktitan.net
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com UK
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com South Africa
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Canada
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com UK
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '26 |
Sale |
2.46 |
43,947 |
108,101 |
591,815 |
| TAHL CINDY | Officer |
Aug 04 '26 |
Proposed Sale |
2.46 |
38,800 |
95,405 |
0 |
| Valamehr Bahram | Officer |
Aug 04 '26 |
Proposed Sale |
2.46 |
43,947 |
108,101 |
0 |
| TAHL CINDY | See Remarks |
May 20 '26 |
Sale |
1.88 |
25,590 |
48,084 |
628,155 |
| Valamehr Bahram | President and CEO |
May 20 '26 |
Sale |
1.88 |
28,946 |
54,482 |
635,762 |
| Valamehr Bahram | Officer |
May 20 '26 |
Proposed Sale |
1.88 |
28,946 |
54,482 |
0 |
| TAHL CINDY | Officer |
May 20 '26 |
Proposed Sale |
1.88 |
25,590 |
48,084 |
0 |
| TAHL CINDY | See Remarks |
May 06 '26 |
Option Exercise |
1.25 |
166,664 |
207,997 |
653,745 |
| EPSTEIN ROBERT S | Director |
May 05 '26 |
Option Exercise |
1.69 |
25,000 |
42,250 |
36,331 |
| RASTETTER WILLIAM H | Director |
May 05 '26 |
Option Exercise |
1.69 |
25,000 |
42,250 |
36,331 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):